On the heels of the full commercial launch of its SmartChip real-time PCR system earlier this month, WaferGen this week reported that it turned its first quarterly profit since the company went public in 2007.

In addition, WaferGen said that its revenues for the second quarter of 2010 grew by more than 500 percent year over year and nearly 10 percent sequentially; and that it was aiming to end 2010 with a four- to five-fold increase in revenues over the previous year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.